Metasyn taps Webb as new CEO
Metasyn has appointed Michael D. Webb as president and CEO ofthe privately held Cambridge, MA, contrast agent developer. Webbassumes the chief executive position from Metasyn founder RandallB. Lauffer, who will remain chair and chief scientific officer.
Metasyn has appointed Michael D. Webb as president and CEO ofthe privately held Cambridge, MA, contrast agent developer. Webbassumes the chief executive position from Metasyn founder RandallB. Lauffer, who will remain chair and chief scientific officer.
Webb comes to Metasyn from Ciba-Corning Diagnostics, wherehe was senior vice president of worldwide marketing and strategicplanning.
The appointment of Webb represents a step in the company'seffort to commercialize its products, which are in advanced preclinicalstudies, according to the firm. Metasyn is developing MS-323,an MRI blood-pool agent that binds reversibly to albumin.
Study: Monitoring of Prostate MRI Exams Could Lead to 75 Percent Reduction of Gadolinium Contrast
March 17th 2025While DCE MRI was deemed helpful in over 67 percent of cases in which it was used, researchers found that monitored prostate MRI exams, which facilitated a 75 percent reduction of DCE MRI sequences, had comparable sensitivity for prostate cancer as non-monitored exams.
